Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia Gravis
NCT03597373 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 99
Last updated 2018-07-24
Summary
Myasthenia gravis (MG) is an autoimmune disease that is characterized by muscle weakness and fatigue. The role of the thymus in MG has been suggested by the evidence that 10% to 15% of patients present with a thymoma and at least 60% with thymus hyperplasia or dysplasia.Beneficial effects of thymectomy in patients with MG have been described in 40% to 90%.Few studies have looked at the incidence of reintubation (not just within 24 hours after extubation), the factors associated with reintubation, and patient outcome.
Premature extubation may lead to hypercarbia, hypoxemia, pulmonary hypertension, right heart failure, and myocardial ischemia. Additionally, it subjects the patient to the physical risks of reintubation, including esophageal intubation, laryngeal trauma, and pulmonary aspiration. The purpose of the present study was to determine the incidence of reintubation, the variables associated with reintubation, and patient outcome
Conditions
Interventions
- OTHER
-
reintubation
Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time
Sponsors & Collaborators
-
First Affiliated Hospital, Sun Yat-Sen University
lead OTHER
Principal Investigators
-
Genglong Liu · First Affiliated Hospital, Sun Yat-Sen University
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2019-01-01
- Completion
- 2019-01-01
Countries
- China
Study Locations
More Related Trials
-
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
NCT01727193 ·Status: COMPLETED ·Phase: PHASE3
-
Application of Artificial Intelligence in Precision Medicine and Healthcare
NCT06879210 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
NCT05332587 ·Status: UNKNOWN ·Phase: PHASE3
-
Myasthenia Gravis Registry in China
NCT06241521 ·Status: RECRUITING
-
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832 ·Status: RECRUITING
-
Detecting Fatigue From Voice in Generalised Myasthenia Gravis
NCT07033559 ·Status: NOT_YET_RECRUITING
-
Markers of Favorable Response to Complement Inhibitors Therapy
NCT06455709 ·Status: RECRUITING
-
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT06617741 ·Status: RECRUITING
-
Tissue Repository for Studies of Myasthenia Gravis
NCT02902536 ·Status: COMPLETED
-
Interleukin and Autoantibodies in Myasthenia Gravis.
NCT05301153 ·Status: UNKNOWN
-
Immune Profiles in Myasthenia Gravis
NCT05095103 ·Status: UNKNOWN
-
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
NCT04535843 ·Status: RECRUITING
-
A Study in Patients With Myasthenia Gravis in China
NCT06700616 ·Status: ACTIVE_NOT_RECRUITING
-
Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis
NCT00987116 ·Status: COMPLETED ·Phase: PHASE4
-
Acupuncture in Myasthenia Gravis (AcuMG)
NCT05230082 ·Status: COMPLETED ·Phase: NA
-
Clinical Prognosis and Progression of Myasthenia Gravis Patients
NCT04101578 ·Status: UNKNOWN
-
Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
NCT06221501 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients :a Prospective Observational Study
NCT04941079 ·Status: UNKNOWN
-
An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06759948 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
NCT05408702 ·Status: COMPLETED
-
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
NCT01325571 ·Status: COMPLETED ·Phase: PHASE3
-
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
NCT01828294 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Myasthenic Crisis in China
NCT04837625 ·Status: RECRUITING
-
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
NCT00424489 ·Status: TERMINATED ·Phase: PHASE1
-
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
NCT00004682 ·Status: TERMINATED ·Phase: NA